p.18 抽出テキスト

Table 4 Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk stratification

Baseline CV toxicity risk factors Anthracycline chemotherapy HER2-targeted

therapies VEGF inhibitors BCR-ABL inhibitors Multiple myeloma

therapies RAF and

MEK inhibitors

Previous CVD HF/cardiomyopathy/ CTRCD VH VH VH H VH VH Severe VHD H H – – – H MI or PCI or CABG H H VH – – H Stable angina H H VH – – H Arterial vascular disease – – VH VH VH – Abnormal ankle-brachial pressure index – – – H – – PH – – – H – – Arterial thrombosis with TKI – – – VH – – Venous thrombosis (DVT/PE) – – H M2 VH – Arrhythmiaa – M2 M2 M2 M2 M1 QTc ≥480 ms – – H H – – 450 ≤QTc , 480 ms (men); 460 ≤QTc , 480 ms (women) – – M2 M2 – – Prior PI CV toxicity – – – – VH – Prior IMiD CV toxicity – – – – H – Cardiac imaging LVEF , 50% H H H H H H LVEF 50–54% M2 M2 M2 – M2 M2 LV hypertrophy – – – – M1 – Cardiac amyloidosis – – – – VH – Cardiac biomarkers Elevated baseline cTnb M1 M2 M1 – M2 M2 Elevated baseline NPb M1 M2 M1 – H M2 Age and CVRF Age ≥80 years H H – – – M1 Age 65–79 years M2 M2 – – – M1 Age ≥75 years – – H H H M1 Age 65–74 years – – M1 M2 M1 M1 Age ≥60 years – – – M1 – – CVD 10-year risk score . 20% – – – H – – Hypertensionc M1 M1 H M2 M1 M2 Chronic kidney diseased M1 M1 M1 M1 M1 M1 Proteinuria – – M1 – – – DMe M1 M1 M1 M1 M1 M1 Hyperlipidaemiaf – – M1 M1 M1 – Family history of thrombophilia – – – M1 M1 –

Continued Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026